Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma
2021 · Molecular Cancer · 70 citations
https://doi.org/10.1186/s12943-021-01465-w
X
Xianyanling Yi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
47
Papers
495
Citations
13
h-index
16
i10-index
Xianyanling Yi is an academic researcher from Sichuan University. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Cancer Immunotherapy and Biomarkers & Bladder and Urothelial Cancer Treatments. The author has an h-index of 13, co-authored 40 publications.
Papers by this author
worksConstruction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy
2023 · Molecular Therapy — Nucleic Acids · 54 citations
https://doi.org/10.1016/j.omtn.2023.07.010
SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs
2022 · Cell Death and Disease · 22 citations
https://doi.org/10.1038/s41419-022-05392-6
ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression
2023 · Military Medical Research · 16 citations
https://doi.org/10.1186/s40779-023-00500-9
Identifying potential risk genes for clear cell renal cell carcinoma with deep reinforcement learning
2025 · Nature Communications · 8 citations
https://doi.org/10.1038/s41467-025-58439-5
Insights into ChatGPT application in renal transplantation
2024 · International Journal of Surgery · 1 citations
https://doi.org/10.1097/js9.0000000000001495
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat